StockNews.com upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) from a sell rating to a hold rating in a research note issued to investors on Friday morning.
A number of other research firms also recently weighed in on ANIP. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, March 3rd. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Guggenheim upped their price target on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target on the stock. Finally, JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday. They issued an “overweight” rating and a $85.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $79.78.
Check Out Our Latest Stock Analysis on ANI Pharmaceuticals
ANI Pharmaceuticals Price Performance
Insiders Place Their Bets
In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the transaction, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Meredith Cook sold 400 shares of the company’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the sale, the vice president now owns 80,545 shares of the company’s stock, valued at $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,700 shares of company stock valued at $610,201 over the last three months. 12.70% of the stock is currently owned by insiders.
Institutional Investors Weigh In On ANI Pharmaceuticals
A number of hedge funds have recently bought and sold shares of ANIP. Pacer Advisors Inc. boosted its holdings in ANI Pharmaceuticals by 23,259.8% during the third quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock valued at $33,907,000 after acquiring an additional 565,910 shares during the period. Millennium Management LLC boosted its holdings in ANI Pharmaceuticals by 89.3% during the fourth quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company’s stock valued at $55,437,000 after acquiring an additional 473,097 shares during the period. JPMorgan Chase & Co. boosted its holdings in ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after acquiring an additional 340,854 shares during the period. abrdn plc bought a new stake in ANI Pharmaceuticals during the fourth quarter valued at about $13,155,000. Finally, Bank of Montreal Can bought a new stake in ANI Pharmaceuticals during the third quarter valued at about $13,043,000. 76.05% of the stock is currently owned by institutional investors.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Read More
- Five stocks we like better than ANI Pharmaceuticals
- Why is the Ex-Dividend Date Significant to Investors?
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- What is the Nasdaq? Complete Overview with History
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- ESG Stocks, What Investors Should Know
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.